Want to see SE:EGTX full AI Analyst Report?
Top Page
Egetis Therapeutics AB
(EGTX)
Select Model
Select Model
Rating:51Neutral
Price Target:
kr7.50
Action:Reiterated
Date:08/22/26
The score is held back primarily by weak financial performance (large ongoing losses and significant negative operating/free cash flow), despite a relatively supportive balance sheet. Technical indicators are a key offset, showing clear positive momentum with the price above major moving averages and a positive MACD. Valuation remains unattractive/unclear due to negative earnings (negative P/E) and no dividend yield data.
Positive Factors
Revenue Growth
TTM revenue reached 66.1M with 39.45% growth, indicating stronger revenue generation. Sustained top-line expansion could gradually improve operating leverage, although the company remains loss-making.
Negative Factors
Severe Cash Burn
Operating cash flow of -300.3M and free cash flow of -301.3M show that operations are not self-funding. Continued burn can require external financing, constrain development flexibility and increase funding risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
TTM revenue reached 66.1M with 39.45% growth, indicating stronger revenue generation. Sustained top-line expansion could gradually improve operating leverage, although the company remains loss-making.
Read all positive factors
Egetis Therapeutics AB (EGTX) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr3.58B
Dividend YieldN/A
Average Volume (3M)842.56K
Price to Earnings (P/E)―
Beta (1Y)-0.34
Revenue Growth39.45%
EPS Growth-1.02%
CountrySE
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.01
Shares Outstanding464,947,240
10 Day Avg. Volume976,106
30 Day Avg. Volume842,560
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr23.00Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.43
Revenue Forecast (FY)kr396.66M
Egetis Therapeutics AB Business Overview & Revenue Model
Company Description
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan dru...
How the Company Makes Money
null...
Egetis Therapeutics AB Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.10M | 62.40M | 46.10M | 57.60M | 22.50M | 38.24M |
| Gross Profit | 11.10M | 12.40M | 34.50M | -146.90M | -120.10M | -58.28M |
| EBITDA | -379.60M | -343.20M | -317.30M | -319.10M | -191.00M | -101.90M |
| Net Income | -405.50M | -342.50M | -343.60M | -326.90M | -189.50M | -104.73M |
Balance Sheet | ||||||
| Total Assets | 760.50M | 639.10M | 792.30M | 760.20M | 561.10M | 569.27M |
| Cash, Cash Equivalents and Short-Term Investments | 378.40M | 215.80M | 351.00M | 303.30M | 127.70M | 143.97M |
| Total Debt | 68.80M | 90.60M | 117.40M | 113.00M | 2.70M | 4.20M |
| Total Liabilities | 278.90M | 300.40M | 299.40M | 214.60M | 54.90M | 42.23M |
| Stockholders Equity | 481.50M | 338.70M | 492.80M | 545.60M | 506.20M | 527.04M |
Cash Flow | ||||||
| Free Cash Flow | -301.30M | -268.60M | -227.90M | -278.40M | -173.50M | -130.28M |
| Operating Cash Flow | -300.30M | -267.10M | -227.90M | -278.40M | -173.50M | -130.11M |
| Investing Cash Flow | -2.70M | -2.80M | -1.20M | -100.00K | -1.70M | -5.96M |
| Financing Cash Flow | 474.00M | 140.00M | 270.90M | 458.90M | 155.70M | -8.90M |
Egetis Therapeutics AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
Egetis Therapeutics AB Corporate Events
Egetis Bolsters Finances and IP as Emcitate Nears Key FDA Decision
Aug 21, 2026
Egetis Therapeutics reported second-quarter 2026 net revenue of SEK 17.4 million from Emcitate sales in Europe, up 23% at constant exchange rates versus a year earlier, while posting a quarterly loss of SEK 108.9 million as it invests in U.S. laun...
Egetis sets Q2 2026 results date as Emcitate nears key FDA decision
Aug 7, 2026
Egetis Therapeutics will publish its second-quarter 2026 report on August 21 and host a same-day conference call offering a corporate and financial update, followed by a QA session, with participation available via webcast or teleconference and a ...
Egetis Backs National Lifetime Re-Air of MCT8 Deficiency Awareness Episode
Jun 10, 2026
Egetis Therapeutics is supporting the national re-airing in the U.S. of a Behind the Mystery episode on Lifetime that spotlights MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome, a rare and life-shortening genetic disorder caused by im...
Egetis Converts Class C Shares After Option Exercise, Boosting Voting Rights
May 29, 2026
Egetis Therapeutics has adjusted its share structure after employees exercised stock options under its 2022–2026 program, converting 3,117,885 class C shares into ordinary shares while keeping the total share count and share capital unchange...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.